Advertisement

Breast Sarcomas

  • Anne Marie Wallace
  • Bret R. Baack
  • Claire F. Verschraegen
Chapter

Abstract

Soft tissue sarcomas are a group of heterogeneous tumor histologies that can occur in any part of the body including the breast. The incidence of primary breast sarcomas is less than 1% of all breast neoplasms. Sarcomas are considered to arise from mesenchymal cells and behave differently than the more common breast tumors of epithelial origin. Other nonepithelial tumors of the breast include lymphomas, malignant melanomas, and extramedullary leukemias (also known as granulocytic sarcomas).

Keywords

Vascular Endothelial Growth Factor Epidermal Growth Factor Receptor Soft Tissue Sarcoma Axillary Lymph Node Dissection Vascular Endothelial Growth Factor Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Khanna S, Gupta S, Khanna NN. Sarcomas of the breast: homogenous or heterogenous? J Surg Oncol. 1981;18:20109–28.CrossRefGoogle Scholar
  2. 2.
    Blanchard DK, Reynolds CA, Grant CS, Donohue JH. Primary nonphylloides breast sarcomas. Am J Surg. 2003;186:359–61.PubMedCrossRefGoogle Scholar
  3. 3.
    Callery CD, Rosen PP, Kinne DW. Sarcoma of the breast. A study of 32 patients with reappraisal of classification and therapy. Ann Surg. 1985;201:527–32.PubMedCrossRefGoogle Scholar
  4. 4.
    Norris HJ, Taylor HB. Sarcomas and related mesenchymal tumors of the breast. Cancer. 1968;22:22–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Pollard SG, Marks PV, Temple LN, Thompson HH. Breast sarcoma. A clinicopathologic review of 25 cases. Cancer. 1990;66:941–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Barnes L, Pietruszka M. Sarcomas of the breast: a clinicopathologic analysis of ten cases. Cancer. 1977;40:1577–85.PubMedCrossRefGoogle Scholar
  7. 7.
    Kennedy T, Biggart JD. Sarcoma of the breast. Br J Cancer. 1967;21:635–44.PubMedCrossRefGoogle Scholar
  8. 8.
    Terrier P, Terrier-Lacombe MJ, Mouriesse H, Friedman S, Spielmann M, Contesso G. Primary breast sarcoma: a review of 33 cases with immunohistochemistry and prognostic factors. Breast Cancer Res Treat. 1989;13:39–48.PubMedCrossRefGoogle Scholar
  9. 9.
    Oberman HA. Sarcomas of the breast. Cancer. 1965;18:1233–43.PubMedCrossRefGoogle Scholar
  10. 10.
    Sailer S. Sarcoma of the breast. Am J Cancer. 1937;31:183–206.Google Scholar
  11. 2010.
    Freter C. Other cancers of the breast. In: Harris Jr ML, Morrow M, Osborne CK, editors. Diseases of the breast. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 683–9.Google Scholar
  12. 12.
    D’Costa GF, Hastak MS, Patil YV. Granulocytic sarcoma of breast: an aleukemic presentation. Indian J Med Sci. 2007;61:152–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Ludgate CM, Anderson TJ, Langlands AO. Sarcoma of the female breast – report of a series of 30 cases. Clin Oncol. 1977;3:97–105.PubMedGoogle Scholar
  14. 14.
    Brown FM, Fletcher CD. Problems in grading soft tissue sarcomas. Am J Clin Pathol. 2000;20104(suppl):S82–9.Google Scholar
  15. 15.
    Zelek L, Llombart-Cussac A, Terrier P, et al. Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol. 2003;21:2583–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Mazeron JJ, Suit HD. Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer. 1987;60:1800–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Leong SP, Cady B, Jablons DM, et al. Clinical patterns of metastasis. Cancer Metastasis Rev. 2006;25:221–32.PubMedCrossRefGoogle Scholar
  18. 18.
    Espat NJ, Lewis JJ. The biological significance of failure at the primary site on ultimate survival in soft tissue sarcoma. Semin Radiat Oncol. 1999;9:369–77.PubMedCrossRefGoogle Scholar
  19. 19.
    Rosen PP, Kimmel M, Ernsberger D. Mammary angiosarcoma. The prognostic significance of tumor differentiation. Cancer. 1988;62:2145–51.PubMedCrossRefGoogle Scholar
  20. 20.
    Adem C, Reynolds C, Ingle JN, Nascimento AG. Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature. Br J Cancer. 2004;91:237–41.PubMedGoogle Scholar
  21. 21.
    Gutman H, Pollock RE, Ross MI, et al. Sarcoma of the breast: implications for extent of therapy. The M. D. Anderson experience. Surgery. 1994;20106:505–9.Google Scholar
  22. 22.
    Berg JW, Decrosse JJ, Fracchia AA, Farrow J. Stromal sarcomas of the breast. A unified approach to connective tissue sarcomas other than cystosarcoma phyllodes. Cancer. 1962;15:418–24.PubMedCrossRefGoogle Scholar
  23. 23.
    Agarwal PK, Mehrotra R. Haemangiosarcoma of the breast. Indian J Cancer. 1977;14:182–5.PubMedGoogle Scholar
  24. 24.
    Myerowitz RL, Pietruszka M, Barnes EL. Primary angiosarcoma of the breast. JAMA. 1978;239:403.PubMedCrossRefGoogle Scholar
  25. 25.
    Liberman L, Dershaw DD, Kaufman RJ, Rosen PP. Angiosarcoma of the breast. Radiology. 1992;183:649–54.PubMedGoogle Scholar
  26. 26.
    Donnell RM, Rosen PP, Lieberman PH, et al. Angiosarcoma and other vascular tumors of the breast. Am J Surg Pathol. 1981;5:629–42.PubMedCrossRefGoogle Scholar
  27. 27.
    Chen KT, Kirkegaard DD, Bocian JJ. Angiosarcoma of the breast. Cancer. 1980;46:368–71.PubMedCrossRefGoogle Scholar
  28. 28.
    Steingaszner LC, Enzinger FM, Taylor HB. Hemangiosarcoma of the breast. Cancer. 1965;18:352–61.PubMedCrossRefGoogle Scholar
  29. 29.
    Barber Jr KW, Harrison EG, Clagett OT, Pratt JH. Angiosarcoma of the breast. Surgery. 1960;48:869–78.PubMedGoogle Scholar
  30. 30.
    Rainwater LM, Martin Jr JK, Gaffey TA, van Heerden JA. Angiosarcoma of the breast. Arch Surg. 1986;121:669–72.PubMedCrossRefGoogle Scholar
  31. 31.
    Hunter TB, Martin PC, Dietzen CD, Tyler LT. Angiosarcoma of the breast. Two case reports and a review of the literature. Cancer. 1985;56:2099–106.PubMedCrossRefGoogle Scholar
  32. 32.
    Jabr FI. Acquired immunodeficiency syndrome-related Kaposi’s sarcoma of the axilla and breast after percutaneous intravenous catheter insertion. Int J Dermatol. 2005;44:62010–2.CrossRefGoogle Scholar
  33. 33.
    Petrek J. Phyllodes tumors. In: LM HJR, Morrow M, Osborne CK, editors. Diseases of the breast. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 669–75.Google Scholar
  34. 34.
    Confavreux C, Lurkin A, Mitton N, et al. Sarcomas and malignant phyllodes tumours of the breast – a retrospective study. Eur J Cancer. 2006;42:2715–21.PubMedCrossRefGoogle Scholar
  35. 35.
    Cohn-Cedermark G, Rutqvist LE, Rosendahl I, Silfversward C. Prognostic factors in cystosarcoma phyllodes. A clinicopathologic study of 77 patients. Cancer. 1991;68:2017–22.PubMedCrossRefGoogle Scholar
  36. 36.
    Hawkins RE, Schofield JB, Fisher C, Wiltshaw E, McKinna JA. The clinical and histologic criteria that predict metastases from cystosarcoma phyllodes. Cancer. 1992;69:141–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Treves N. A study of cystosarcoma phyllodes. Ann N Y Acad Sci. 1964;20104:922–36.Google Scholar
  38. 38.
    Salvadori B, Cusumano F, Del Bo R, et al. Surgical treatment of phyllodes tumors of the breast. Cancer. 1989;63:2532–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Oberman HA. Cystosarcoma phyllodes; a clinicopathologic study of hypercellular periductal stromal neoplasms of breast. Cancer. 1965;18:697–710.PubMedCrossRefGoogle Scholar
  40. 40.
    Zissis C, Apostolikas N, Konstantinidou A, Griniatsos J, Vassilopoulos PP. The extent of surgery and prognosis of patients with phyllodes tumor of the breast. Breast Cancer Res Treat. 1998;48:205–10.PubMedCrossRefGoogle Scholar
  41. 41.
    Contarini O, Urdaneta LF, Hagan W, Stephenson Jr SE. Cystosarcoma phylloides of the breast: a new therapeutic proposal. Am Surg. 1982;48:157–66.PubMedGoogle Scholar
  42. 42.
    McDivitt RW, Urban JA, Farrow JH. Cystosarcoma phyllodes. Johns Hopkins Med J. 1967;120:33–45.PubMedGoogle Scholar
  43. 43.
    Curran RC, Dodge OG. Sarcoma of breast, with particular reference to its origin from fibroadenoma. J Clin Pathol. 1962;15:1–16.PubMedCrossRefGoogle Scholar
  44. 44.
    Hart J, Layfield LJ, Trumbull WE, Brayton D, Barker WF, Giuliano AE. Practical aspects in the diagnosis and management of cystosarcoma phyllodes. Arch Surg. 1988;123:1079–83.PubMedCrossRefGoogle Scholar
  45. 45.
    Reinfuss M, Mitus J, Stelmach A. Phyllodes tumor of the breast. Strahlenther Onkol. 1995;171:5–2010.PubMedGoogle Scholar
  46. 46.
    Reinfuss M, Mitus J, Duda K, Stelmach A, Rys J, Smolak K. The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer. 1996;77:910–6.PubMedCrossRefGoogle Scholar
  47. 47.
    National Comprehensive Cancer Network practice guidelines in oncology; breast cancer. http://nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed 8 Sep 2007.
  48. 48.
    Zurrida S, Bartoli C, Galimberti V, et al. Which therapy for unexpected phyllode tumour of the breast? Eur J Cancer. 1992;28:654–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Ben Hassouna J, Damak T, Gamoudi A, et al. Phyllodes tumors of the breast: a case series of 106 patients. Am J Surg. 2006;192:141–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Pisters PW, Bramwell VH, Rubin BP, O’Sullivan B. Sarcomas of soft tissue. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, editors. Abeloff: clinical oncology. 3rd ed. Philadelphia: Elsevier/Churchill Livingstone; 2004.Google Scholar
  51. 51.
    Khalbuss WE. Cytomorphology of rare malignant tumors of the breast. Clin Lab Med 2005;25:761–75; vii.Google Scholar
  52. 52.
    Al-Nafussi A. Spindle cell tumours of the breast: practical approach to diagnosis. Histopathology. 1999;35:1–13.PubMedCrossRefGoogle Scholar
  53. 53.
    Reis-Filho JS, Pinheiro C, Lambros MB, et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol. 2006;209:445–53.PubMedCrossRefGoogle Scholar
  54. 54.
    Tse GM, Tan PH, Putti TC, Lui PC, Chaiwun B, Law BK. Metaplastic carcinoma of the breast: a clinicopathological review. J Clin Pathol. 2006;59:1079–83.PubMedCrossRefGoogle Scholar
  55. 55.
    Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema: a report of six cases in elephanthiasis chirurgica. Cancer. 1948;1:64–81.PubMedCrossRefGoogle Scholar
  56. 56.
    Noguchi M, Hasegawa H, Tajiri K, et al. Stewart-Treves syndrome. A report of two cases with a review of Japanese literature. Jpn J Surg. 1987;17:407–12.PubMedCrossRefGoogle Scholar
  57. 57.
    Clements WD, Kirk SJ, Spence RA. A rare late complication of breast cancer treatment. Br J Clin Pract. 1993;47:219–20.PubMedGoogle Scholar
  58. 58.
    Aygit AC, Yildirim AM, Dervisoglu S. Lymphangiosarcoma in chronic lymphoedema. Stewart-Treves syndrome. J Hand Surg (Edinburgh, Lothian). 1999;24:135–7.CrossRefGoogle Scholar
  59. 59.
    Kyriazis AP, Kyriazis AA. Primary rhabdomyosarcoma of the female breast: report of a case and review of the literature. Arch Pathol Lab Med. 1998;122:747–9.PubMedGoogle Scholar
  60. 60.
    Chateil JF, Arboucalot F, Perel Y, Brun M, Boisserie-Lacroix M, Diard F. Breast metastases in adolescent girls: US findings. Pediatr Radiol. 1998;28:832–5.PubMedCrossRefGoogle Scholar
  61. 61.
    Hays DM, Donaldson SS, Shimada H, et al. Primary and metastatic rhabdomyosarcoma in the breast: neoplasms of adolescent females, a report from the Intergroup Rhabdomyosarcoma Study. Med Pediatr Oncol. 1997;29:181–9.PubMedCrossRefGoogle Scholar
  62. 62.
    National Comprehensive Cancer Network Practice guidelines in oncology; genetic/familial high-risk assessment: breast and ovarian. NCCN.org, 2007. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 8 Sep 2007.
  63. 63.
    Hung J, Anderson R. p53: functions, mutations and sarcomas. Acta Orthop Scand. 1997;273:68–73.Google Scholar
  64. 64.
    Engel A, Lamm SH, Lai SH. Human breast sarcoma and human breast implantation: a time trend analysis based on SEER data (1973-1990). J Clin Epidemiol. 1995;48:539–44.PubMedCrossRefGoogle Scholar
  65. 65.
    Hoshaw SJ, Klein PJ, Clark BD, Cook RR, Perkins LL. Breast implants and cancer: causation, delayed detection, and survival. Plast Reconstr Surg. 2001;107:1393–407.PubMedCrossRefGoogle Scholar
  66. 66.
    Yap J, Chuba PJ, Thomas R, et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2002;52:1231–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Kirova YM, Vilcoq JR, Asselain B, Sastre-Garau X, Fourquet A. Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. Cancer. 2005;104:856–63.PubMedCrossRefGoogle Scholar
  68. 68.
    Blanchard DK, Reynolds C, Grant CS, Farley DR, Donohue JH. Radiation-induced breast sarcoma. Am J Surg. 2002;184:356–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Kirova YM, Feuilhade F, Calitchi E, Otmezguine Y, Belembaogo E, Le Bourgeois JP. [Radiation-induced sarcoma after breast cancer. Apropos of 8 cases and review of the literature]. Cancer Radiothér. 1998;2:381–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Karlsson P, Holmberg E, Samuelsson A, Johansson KA, Wallgren A. Soft tissue sarcoma after treatment for breast cancer – a Swedish population-based study. Eur J Cancer. 1998;34:2068–75.PubMedCrossRefGoogle Scholar
  71. 71.
    Marchal C, Weber B, de Lafontan B, et al. Nine breast angiosarcomas after conservative treatment for breast carcinoma: a survey from French comprehensive Cancer Centers. Int J Radiat Oncol Biol Phys. 1999;44:20103–9.CrossRefGoogle Scholar
  72. 72.
    Kilpatrick SE. Histologic prognostication in soft tissue sarcomas: grading versus subtyping or both? A comprehensive review of the literature with proposed practical guidelines. Ann Diagn Pathol. 1999;3:48–61.PubMedCrossRefGoogle Scholar
  73. 73.
    Costa J, Wesley RA, Glatstein E, Rosenberg SA. The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer. 1984;53:530–41.PubMedCrossRefGoogle Scholar
  74. 74.
    Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001;91:1914–26.PubMedCrossRefGoogle Scholar
  75. 75.
    Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg. 1999;229:602–10; discussion 610–2.Google Scholar
  76. 76.
    Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2, 185 patients treated with anthracycline-containing first-line regimens – a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 1999;17:150–7.PubMedGoogle Scholar
  77. 77.
    Vogt-Moykopf I, Bulzebruck H, Merkle NM, Probst G. Results of surgical treatment of pulmonary metastases. Eur J Cardiothorac Surg. 1988;2:224–32.PubMedCrossRefGoogle Scholar
  78. 78.
    Choong PF, Pritchard DJ, Rock MG, Sim FH, Frassica FJ. Survival after pulmonary metastasectomy in soft tissue sarcoma. Prognostic factors in 214 patients. Acta Orthop Scand. 1995;66:561–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Elwady N, Ousehal A, Alibou F, Tazi Z, Boukind H, Kadiri R. [Angiosarcoma of the breast. Radiological aspects. About one case]. J Radiol. 2000;81:50–3.PubMedGoogle Scholar
  80. 80.
    National Comprehensive Cancer Network Clinical practice guidelines in oncology; soft tissue sarcomas. NCCN.org 2007. http://nccn.org/professionals/physician_gls/PDF/sarcoma.pdf. Accessed 9 Aug 2007.
  81. 81.
    Luzzatto R, Grossmann S, Scholl JG, Recktenvald M. Postradiation pleomorphic malignant fibrous histiocytoma of the breast. Acta Cytol. 1986;30:48–50.PubMedGoogle Scholar
  82. 82.
    Rupp M, Hafiz MA, Khalluf E, Sutula M. Fine needle aspiration in stromal sarcoma of the breast. Light and electron microscopic findings with histologic correlation. Acta Cytol. 1988;32:72–4.PubMedGoogle Scholar
  83. 83.
    Heslin MJ, Lewis JJ, Woodruff JM, Brennan MF. Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol. 1997;4:425–31.PubMedCrossRefGoogle Scholar
  84. 84.
    Ball AB, Fisher C, Pittam M, Watkins RM, Westbury G. Diagnosis of soft tissue tumours by Tru-Cut biopsy. Br J Surg. 1990;77:756–8.PubMedCrossRefGoogle Scholar
  85. 85.
    Skrzynski MC, Biermann JS, Montag A, Simon MA. Diagnostic accuracy and charge-savings of outpatient core needle biopsy compared with open biopsy of musculoskeletal tumors. J Bone Joint Surg. 1996;78:644–9.PubMedGoogle Scholar
  86. 86.
    Brennan M, Singer S, Maki R, O’Sullivan B. Sarcomas of the soft tissues and bone. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practie of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1581–637.Google Scholar
  87. 87.
    Schwartz HS, Spengler DM. Needle tract recurrences after closed biopsy for sarcoma: three cases and review of the literature. Ann Surg Oncol. 1997;4:228–36.PubMedCrossRefGoogle Scholar
  88. 88.
    Yang WT, Hennessy BT, Dryden MJ, Valero V, Hunt KK, Krishnamurthy S. Mammary angiosarcomas: imaging findings in 24 patients. Radiology. 2007;242:725–34.PubMedCrossRefGoogle Scholar
  89. 89.
    Kikawa Y, Konishi Y, Nakamoto Y, et al. Angiosarcoma of the breast – specific findings of MRI. Breast Cancer. 2006;13:369–73.PubMedCrossRefGoogle Scholar
  90. 90.
    Yabuuchi H, Soeda H, Matsuo Y, et al. Phyllodes tumor of the breast: correlation between MR findings and histologic grade. Radiology. 2006;241:702–9.PubMedCrossRefGoogle Scholar
  91. 91.
    Kinoshita T, Fukutomi T, Kubochi K. Magnetic resonance imaging of benign phyllodes tumors of the breast. Breast J. 2004;10:232–6.PubMedCrossRefGoogle Scholar
  92. 92.
    Bakheet SM, Powe J, Ezzat A, Al Suhaibani H, Tulbah A, Rostom A. F-18 FDG whole-body positron emission tomography scan in primary breast sarcoma. Clin Nucl Med. 1998;23:604–8.PubMedCrossRefGoogle Scholar
  93. 93.
    National Comprehensive Cancer Network practice guidelines in oncology, breast cancer. NCCN.org 2007. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 28 March 2007.
  94. 94.
    Losanoff JE, Jaber S, Esuba M, Perry M, Sauter ER. Primary angiosarcoma of the breast: do enlarged axillary nodes matter? Breast J. 2006;12:371–4.PubMedCrossRefGoogle Scholar
  95. 95.
    Barrow BJ, Janjan NA, Gutman H, et al. Role of radiotherapy in sarcoma of the breast–a retrospective review of the M.D. Anderson experience. Radiother Oncol. 1999;52:173–8.PubMedCrossRefGoogle Scholar
  96. 96.
    McGowan TS, Cummings BJ, O’Sullivan B, Catton CN, Miller N, Panzarella T. An analysis of 78 breast sarcoma patients without distant metastases at presentation. Int J Radiat Oncol Biol Phys. 2000;46:383–90.PubMedCrossRefGoogle Scholar
  97. 97.
    Skinner KA, Eilber FR. Soft tissue sarcoma nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996;5:121–7.PubMedGoogle Scholar
  98. 98.
    Blazer III DG, Sabel MS, Sondak VK. Is there a role for sentinel lymph node biopsy in the management of sarcoma? Surg Oncol. 2003;12:201–6.PubMedCrossRefGoogle Scholar
  99. 99.
    Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg. 1993;217:72–7.PubMedCrossRefGoogle Scholar
  100. 100.
    van Akkooi AC, Verhoef C, van Geel AN, Kliffen M, Eggermont AM, de Wilt JH. Sentinel node biopsy for clear cell sarcoma. Eur J Surg Oncol. 2006;32:996–9.PubMedCrossRefGoogle Scholar
  101. 101.
    Kuerer HM. Breast cancer axillary surgery: before, after, or none at all? Ann Surg Oncol. 2006.Google Scholar
  102. 102.
    Shetty MK, Carpenter WS. Sonographic evaluation of isolated abnormal axillary lymph nodes identified on mammograms. J Ultrasound Med. 2004;23:63–71.PubMedGoogle Scholar
  103. 103.
    Khirwadkar N, Dey P, Das A, Gupta SK. Fine-needle aspiration biopsy of metastatic soft-tissue sarcomas to lymph nodes. Diagn Cytopathol. 2001;24:229–32.PubMedCrossRefGoogle Scholar
  104. 104.
    Greene FL, Compton CC, Fritz AG, Shah JP, Winchester DP, editors. American Joint Committee on Cancer Staging atlas. New York: Springer; 2006.Google Scholar
  105. 105.
    Norris HJ, Taylor HB. Relationship of histologic features to behavior of cystosarcoma phyllodes. Analysis of ninety-four cases. Cancer. 1967;20:2090–9.PubMedCrossRefGoogle Scholar
  106. 106.
    Reinfuss M, Mitus J, Smolak K, Stelmach A. Malignant phyllodes tumours of the breast. A clinical and pathological analysis of 55 cases. Eur J Cancer. 1993;29A:1252–6.PubMedCrossRefGoogle Scholar
  107. 107.
    Palmer ML, De Risi DC, Pelikan A, et al. Treatment options and recurrence potential for cystosarcoma phyllodes. Surg Gynecol Obstet. 1990;170:193–6.PubMedGoogle Scholar
  108. 108.
    Gilcrease MZ. Sarcomatoid breast tumors have sarcomatoid behavior. Am J Surg Pathol 2007;31:326–7; author reply 7.Google Scholar
  109. 109.
    Carter MR, Hornick JL, Lester S, Fletcher CD. Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol. 2006;30:300–9.PubMedGoogle Scholar
  110. 20100.
    Yang JC, Glastein EJ, Rosenberg SA, et al. Sarcomas of soft tissues. In: De Vita Jr SH VT, Rosenberg SA, editors. Principles and practice of oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 1993. p. 1436–88.Google Scholar
  111. 20101.
    Christensen L, Schiodt T, Blichert-Toft M. Sarcomatoid tumours of the breast in Denmark from 1977 to 1987. A clinicopathological and immunohistochemical study of 100 cases. Eur J Cancer. 1993;29A:1824–31.PubMedCrossRefGoogle Scholar
  112. 20102.
    Lewis JJ, Leung D, Heslin M, Woodruff JM, Brennan MF. Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. J Clin Oncol. 1997;15:646–52.PubMedGoogle Scholar
  113. 20103.
    Lewis JJ, Brennan MF. Soft tissue sarcomas. Curr Probl Surg. 1996;33:817–72.PubMedCrossRefGoogle Scholar
  114. 20104.
    Johnstone PA, Pierce LJ, Merino MJ, Yang JC, Epstein AH, DeLaney TF. Primary soft tissue sarcomas of the breast: local-regional control with post-operative radiotherapy. Int J Radiat Oncol Biol Phys. 1993;27:671–5.PubMedCrossRefGoogle Scholar
  115. 20105.
    Mattoch IW, Robbins JB, Kempson RL, Kohler S. Post-radiotherapy vascular proliferations in mammary skin: a clinicopathologic study of 2010 cases. J Am Acad Dermatol. 2007;57:126–33.PubMedCrossRefGoogle Scholar
  116. 20106.
    Buatti JM, Harari PM, Leigh BR, Cassady JR. Radiation-induced angiosarcoma of the breast. Case report and review of the literature. Am J Clin Oncol. 1994;17:444–7.PubMedCrossRefGoogle Scholar
  117. 20107.
    Taghian A, de Vathaire F, Terrier P, et al. Long-term risk of sarcoma following radiation treatment for breast cancer. Int J Radiat Oncol Biol Phys. 1991;21:361–7.PubMedCrossRefGoogle Scholar
  118. 20108.
    Arbabi L, Warhol MJ. Pleomorphic liposarcoma following radiotherapy for breast carcinoma. Cancer. 1982;49:878–80.PubMedCrossRefGoogle Scholar
  119. 20109.
    Rubino C, Shamsaldin A, Le MG, et al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat. 2005;89:277–88.PubMedCrossRefGoogle Scholar
  120. 120.
    Kirova YM, Gambotti L, De Rycke Y, Vilcoq JR, Asselain B, Fourquet A. Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review. Int J Radiat Oncol Biol Phys. 2007;68:359–63.PubMedCrossRefGoogle Scholar
  121. 121.
    Laskin WB, Silverman TA, Enzinger FM. Postradiation soft tissue sarcomas. An analysis of 53 cases. Cancer. 1988;62:2330–40.PubMedCrossRefGoogle Scholar
  122. 122.
    Stewart NJ, Pritchard DJ, Nascimento AG, Kang YK. Lymphangiosarcoma following mastectomy. Clinical Orthop Relat Res. 1995;320:135–41.Google Scholar
  123. 123.
    Kaufmann T, Chu F, Kaufman R. Post-mastectomy lymphangiosarcoma (Stewart-Treves syndrome): report of two long-term survivals. Br J Radiol. 1991;64:857–60.PubMedCrossRefGoogle Scholar
  124. 124.
    Cahan WG, Woodard HQ, Higinbotham NL, et al. Sarcoma arising in irradiated bone; report of eleven cases. Cancer. 1948;1:3–29.PubMedCrossRefGoogle Scholar
  125. 125.
    Rietjens M, Urban CA, Rey PC, et al. Long-term oncological results of breast conservative treatment with oncoplastic surgery. Breast. 2007;16:387–95.PubMedCrossRefGoogle Scholar
  126. 126.
    Petit JY, Garusi C, Greuse M, et al. One hundred and eleven cases of breast conservation treatment with simultaneous reconstruction at the European Institute of Oncology (Milan). Tumori. 2002;88:41–7.PubMedGoogle Scholar
  127. 127.
    Trent II IJ, Benjamin RS, Valero V. Primary soft tissue sarcoma of the breast. Curr Treat Options Oncol. 2001;2:169–76.CrossRefGoogle Scholar
  128. 128.
    Keohan ML, Taub RN. Chemotherapy for advanced sarcoma: therapeutic decisions and modalities. Semin Oncol. 1997;24:572–9.PubMedGoogle Scholar
  129. 129.
    Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824–31.PubMedCrossRefGoogle Scholar
  130. 130.
    Leu KM, Ostruszka LJ, Shewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. 2004;22:1706–12.PubMedCrossRefGoogle Scholar
  131. 131.
    Kostler WJ, Brodowicz T, Attems Y, et al. Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. Ann Oncol. 2001;12:1281–8.PubMedCrossRefGoogle Scholar
  132. 132.
    Edmonson JH. Chemotherapeutic assessment and approaches. Int J Radiat Oncol Biol Phys. 1976;1:747–8.PubMedCrossRefGoogle Scholar
  133. 133.
    Spath-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs. 2000;2010:325–9.CrossRefGoogle Scholar
  134. 134.
    Svancarova L, Blay JY, Judson IR, et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002;38:556–9.PubMedCrossRefGoogle Scholar
  135. 135.
    Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E. Phase II trial of gemcitabine in advanced sarcomas. Cancer. 2002;94:3225–9.PubMedCrossRefGoogle Scholar
  136. 136.
    Okuno S, Ryan LM, Edmonson JH, Priebat DA, Blum RH. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer. 2003;97:1969–73.PubMedCrossRefGoogle Scholar
  137. 137.
    Amodio A, Carpano S, Manfredi C, et al. Gemcitabine in advanced stage soft tissue sarcoma: a phase II study. Clin Ter. 1999;150:17–20.PubMedGoogle Scholar
  138. 138.
    D’Incalci M, Jimeno J. Preclinical and clinical results with the natural marine product ET-743. Expert Opin Investig Drugs. 2003;12:1843–53.PubMedCrossRefGoogle Scholar
  139. 139.
    Demetri GD, Manola J, Harmon D, et al. Ecteinascidin-743 (ET-743) induces durable responses and promising 1-year survival rates in soft tissue sarcomas: final results of Phase II and pharmacokinetic studies in the U.S.A. Proc Am Soc Clin Oncol. 2001;20:A1406.Google Scholar
  140. 140.
    LeCesne A, Blay JY, Judson I, et al. ET-743 is an active drug in adult soft tissue sarcomas; a STBSG-EORTC Phase II Trial. Proc Am Soc Clin Oncol. 2001;20:A1407.Google Scholar
  141. 141.
    Yovine A, Riofrio M, Brain E, et al. Ecteinascidin (ET-743) given as a 24 hour intravenous continuous infusion every 3 weeks: Results of a Phase II Trial in patients with pretreated soft tissue sarcomas. Proc Am Soc Clin Oncol. 2001.Google Scholar
  142. 142.
    Verschraegen CF, Glover K. ET-743 (PharmaMar/NCI/Ortho Biotech). Curr Opin Investig Drugs. 2001;2:1631–8.PubMedGoogle Scholar
  143. 143.
    Balasubramanian L, Evens AM. Targeting angiogenesis for the treatment of sarcoma. Curr Opin Oncol. 2006;18:354–9.PubMedCrossRefGoogle Scholar
  144. 144.
    Potti A, Ganti AK, Foster H, et al. Immunohistochemical detection of HER-2/neu, c-kit (CD20107) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas. Anticancer Res. 2004;24:333–7.PubMedGoogle Scholar
  145. 145.
    Hayes AJ, Mostyn-Jones A, Koban MU, A’Hern R, Burton P, Thomas JM. Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg. 2004;91:242–7.PubMedCrossRefGoogle Scholar
  146. 146.
    D’Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol. 2005;23:7135–42.PubMedCrossRefGoogle Scholar
  147. 147.
    Verschraegen CV, Fekrazad MH, QuinnR, Rabinowitz I, Muller CY, Smith HO, Wallace AM, Purdy M, Judson P, Blithman M, Snyder D. Phase I/II study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma. ASCO 2007.Google Scholar
  148. 148.
    Zaman K, Driscoll R, Hahn D, et al. Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. Int J Cancer. 2006;20108:755–64.CrossRefGoogle Scholar
  149. 149.
    Herbst RS, Kies MS. Gefitinib: current and future status in cancer therapy. Clin Adv Hematol Oncol. 2003;1:466–72.PubMedGoogle Scholar
  150. 150.
    Miettinen M, Lasota J. KIT (CD20107): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005;13:205–20.PubMedCrossRefGoogle Scholar
  151. 151.
    Dvorak J, Zoul Z, Melichar B, et al. Liposomal doxorubicin combined with regional hyperthermia: reducing systemic toxicity and improving locoregional efficacy in the treatment of solid tumors. J Chemother (Florence, Italy). 2004;16 suppl 5:34–6.Google Scholar
  152. 152.
    Edge SB, Byrd DR, Compton CC, editors. Soft tissue sarcoma. In: AJCC cancer staging manual. 7th ed. New York: Springer; 2010:291–298.Google Scholar
  153. 153.
    van Hoesel QG, Verweij J, Catimel G, et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol. 1994;5:539–42.PubMedGoogle Scholar
  154. 154.
    Hartmann JT, Oechsle K, Huober J, et al. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Investig New Drugs. 2006;24:249–53.CrossRefGoogle Scholar

Copyright information

© Springer New York 2010

Authors and Affiliations

  • Anne Marie Wallace
    • 1
  • Bret R. Baack
  • Claire F. Verschraegen
  1. 1.Department of SurgeryCancer Research and Treatment Center, University of New MexicoAlbuquerqueUSA

Personalised recommendations